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Background: Evidence is needed about the promptness of cancer diagnosis and associations between its measures.
Methods: We analysed data from the National Audit of Cancer Diagnosis in Primary Care 2009–10 exploring the association
between the interval from first symptomatic presentation to specialist referral (the primary care interval, or ‘interval’ hereafter) and
the number of pre-referral consultations.
Results: Among 13 035 patients with any of 18 different cancers, most (82%) were referred after 1 (58%) or 2 (25%) consultations
(median intervals 0 and 15 days, respectively) while 9%, 4% and 5% patients required 3, 4 or 5þ consultations (median intervals 34,
47 and 97 days, respectively) (Spearman’s r¼ 0.70). The association was at least moderate for any cancer (Spearman’s r range: 0.55
(prostate) 0.77 (brain)). Patients with cancers with a higher proportion of three or more pre-referral consultations typically also
had longer median intervals (e.g., multiple myeloma) and vice versa (e.g., breast cancer).
Conclusion: The number of pre-referral consultations has construct validity as a measure of the primary care interval. Developing
interventions to reduce the number of pre-referral consultations can help improve the timeliness of cancer diagnosis, and
constitutes a priority for early diagnosis initiatives and research.
In spite of its potential importance (Richards et al, 1999; Thomson
and Forman, 2009; Tørring et al, 2011) there is currently no
uniform approach to measuring the timeliness of cancer diagnosis.
The time between the first symptomatic presentation of a cancer
patient to a general practitioner and their first specialist referral for
further investigation (i.e., the ‘primary care interval’) is a relatively
established measure (Allgar and Neal, 2005; Neal and Allgar, 2005;
Hansen et al, 2011; Weller et al, 2012). The number of
consultations with a general practitioner before hospital referral
is increasingly being used as a measure of the promptness of cancer
diagnosis (Pancreatic Cancer UK, 2011; Rarer Cancer Foundation,
2011; Rubin et al, 2011; The Roy Castle Lung Cancer Foundation,
2011; Anonymous, 2012; Lyratzopoulos et al, 2012; Teenage
Cancer Trust, 2012).
Both measures (i.e., both the primary care interval and the
number of pre-referral consultations) have specific strengths and
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weaknesses, some of which are shared (see Online Supplementary
Information, Table). Exploring whether and how the two measures
are associated is important: If strongly correlated, both or either can
be used for research and quality surveillance; if weakly correlated,
using the number of pre-referral consultations as a measure of
timeliness should be discouraged. Importantly, if the number of pre-
referral consultations is a valid surrogate of the primary care
interval, earlier diagnosis efforts could focus on improving the
sensitivity of symptom appraisal by general practitioners during a
medical consultation, for example, using clinical decision support
tools (Hamilton, 2009; Hippisley-Cox and Coupland, 2012). We
therefore examined the association between the number of pre-
referral consultations and the primary care interval.
MATERIALS AND METHODS
We analysed data from the (English) National Audit of Cancer
Diagnosis in Primary Care (2009–2010), undertaken as part of the
National Awareness and Early Diagnosis Initiative (Cancer
Research UK, 2009; Rubin et al, 2011). Data were collected by
general practitioners or other professionals in an estimated total of
1170 general practices (B14% of all practices in England) who
participated voluntarily. Comparisons with cancer registration
statistics indicate good representativeness (Rubin et al, 2011). We
analysed data on patients aged 15 years or older with completely
observed information on number of pre-referral consultations and
primary care interval values from 0 to 730 days. Because of sample
size considerations, analysis was restricted to patients with the 18
most numerous cancers.
We calculated the median primary care interval (in days) and
inter-quartile range for different numbers of pre-referral consulta-
tions. This was done both for all patients and separately by cancer.
Box plots were used to further illustrate these data. Given the right-
skewed nature of primary care interval data, we calculated the
Spearman’s rank correlation co-efficient of the two measures.
Subsequently, we calculated the receiver–operator characteristic
(ROC) area under the curve (AUC), treating the primary care
interval as a continuous variable and the number of pre-referral
consultations as a binary variable (‘three or more’ vs ‘one or two’
consultations—as used by UK policy makers (NHS, 2011)).
Using linear regression we explored whether the association
between the two measures varied between different patients
groups. Owing to data non-normality, significance testing
was based on bootstrapping (1000 samples). See also Online
Supplementary Information.
RESULTS
Among 13 035 patients included in the analysis the median (inter-
quartile range) primary care interval was 5 (0–23) days. Most
(82%) were referred after 1 (57.5%) or 2 (24.6%) consultations,
with median primary care interval (inter-quartile range) of 0 (0–3)
and 15 (7–31) days, respectively. Of the 18% that required 3
(9.2%), 4 (3.9%) or ‘5 or more’ (4.8%) consultations, the median
primary care interval (inter-quartile range) was 34 (16–64), 47
(27–90) and 97 (46–173) days, respectively (Table 1, Figure 1).
Similar patterns were observed for patients with any of the 18
cancers (Table 1). Patients with multiple myeloma and lung cancer
had high proportions of three or more pre-referral consultations
(46% and 33%, respectively) and long median primary care
intervals (21 and 14 days, respectively). Patients with breast cancer
and melanoma had the lowest proportion of three or more pre-
referral consultations (3% and 5%, respectively) and the shortest
median primary care intervals (0 days for both).
For patients with any of the 18 cancers the Spearman’s r was
0.70 (Po0.0001) and the ROC AUC was 0.88 (95% confidence
interval: 0.87–0.89) (Table 2). Primary care interval cutoff values of
either 17 or 18 days have sensitivity and specificity of 0.80 or
higher for predicting pre-referral consultation category.
Using linear regression we found no evidence for interactions
between the number of pre-referral consultations and age, sex or
ethnicity (P¼ 0.998, P¼ 0.261 and P¼ 0.691, respectively), but
strong evidence for interaction with cancer type (Po0.001).
Nevertheless, the association was at least moderately strong for
each cancer (Spearman’s r range: from 0.55 to 0.77 for prostate and
brain cancer, respectively, Table 2). There was evidence for an
interaction between the number of pre-referral consultations and
different referral types (P¼ 0.016), however the association was
strong for any referral type (Spearman’s r range: from 0.67 to 0.72
for routine and ‘2-week’ referrals, respectively, Table 2). See also
Online Supplementary Information.
DISCUSSION
Using data from the English National Audit of Cancer Diagnosis in
Primary Care we found that the number of pre-referral consulta-
tions has construct validity as a measure of the primary care
interval. The association between the two measures was strong for
patients with any type of hospital referral and either moderate or
strong for patients with any of the studied cancers. Patients with
cancers requiring greater number of consultations tended to have
longer primary care intervals (e.g., multiple myeloma) and vice
versa (e.g., breast cancer).
The findings allow us to gain some insight into the potential
reduction in primary care interval that could be achievable by
reducing the number of pre-referral consultations. For example,
the median primary care interval for patients with ‘five or more’
pre-referral consultations was 49.5, 62.5 and 81.5 days longer than
those with four, three and two consultations, respectively. Such
gains in the timeliness of diagnosis could potentially be achievable
if patients with different number of consultations present with
similar symptoms. These illustrations should therefore be con-
sidered to represent the theoretical maximum potential for
improvement (in timeliness that could be achievable by reducing
the number of pre-referral consultations) given the state of medical
knowledge and system factors at the time of the audit period (such
as the extent of access to specialist investigation available to general
practitioners).
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Figure 1. Box plot for primary care interval by category of number of
pre-referral consultations (1, 2, 3, 4 and ‘5þ ’) for patients with any of 18
cancers (n¼ 13035).
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A correlation between pre-referral consultations and duration of
primary care interval might be intuitive but evidence about this
association is sparse (Bjerager et al, 2006). The findings
corroborate evidence suggesting that suspecting the diagnosis of
cancer is generally more challenging for cancers without specific
symptoms (e.g., multiple myeloma, stomach cancer) compared
with cancers with specific signs and symptoms (breast cancer,
melanoma) (Rubin et al, 2011; Lyratzopoulos et al, 2012).
Strengths of our study include its large sample size, the inclusion
of patients with 18 different cancers and the use of a range of
analytical approaches. There are several weaknesses. Some
consultations may have been misclassified, either because of poor
recording of presenting symptoms or misattribution of recorded
symptoms—particularly in the context of co-morbidity (Weller
et al, 2012). However, we judge that such errors are unlikely to
have introduced substantial bias. Although there was no indepen-
dent validation of the audit data, patients responding to the (2010)
Cancer Patient Experience Survey reported similar patterns of
variation by cancer in relation to the number of pre-referral
consultations (Lyratzopoulos et al, 2012). Considering generalisa-
bility, although patients included in the audit reflect national
incidence statistics in respect of cancer type, age and sex (Rubin
et al, 2011), it is conceivable that organisational factors and care
quality in participating practices were different to other (non-
participating) practices. Finally, we could not examine whether any
of the prolonged values of either the primary care interval or the
number of pre-referral consultations were either justifiable or
preventable.
A more liberal policy for referral and investigation of
patients with non-specific symptoms may increase the number of
cancer patients diagnosed after one or two consultations;
but at the expense of additional patient anxiety and healthcare
utilisation costs for patients who will be investigated but found
not to have cancer. Wider access by general practitioners to
specialist diagnostic tests is increasingly being advocated
(Department of Health, 2012). There is a need to monitor
the impact of general practitioner-led investigations on the
promptness of diagnosis of cancer (and other pathologies) and
on resource use. This can be achieved by a programme of
primary care audit that encompasses use of diagnostic
imaging or endoscopic investigations. Point-Of-Care diagnostic
technologies can also have a part in reducing the number of
consultations before referral, and such tests merit further
development and evaluation.
Table 2. Spearman’s rank correlation co-efficient and ROC AUC values for the association between primary care interval and category of number of pre-
referral consultations (n¼13 035)
N Spearman’s r Spearman’s rP-value
ROC area under
the curvea
ROC area 95%
lower CI
ROC area 95%
upper CI
All patients 13035 0.70 o0.0001 0.88 0.87 0.89
By cancer
Breast 2367 0.56 0.96 0.93 0.98
Prostate 2201 0.55 0.84 0.82 0.86
Colorectal 1999 0.71 0.86 0.84 0.88
Lung 1421 0.62 0.83 0.81 0.86
Melanoma 735 0.61 0.87 0.81 0.94
Bladder 721 0.72 0.90 0.87 0.93
Lymphoma 590 0.70 0.87 0.84 0.90
Oesophageal 500 0.75 0.87 0.84 0.91
Endometrial 358 0.64 o0.0001b 0.89 0.84 0.94
Leukaemia 358 0.59 0.81 0.76 0.87
Ovarian 324 0.68 0.86 0.82 0.91
Pancreatic 303 0.71 0.89 0.85 0.93
Renal 272 0.60 0.84 0.79 0.90
Stomach 237 0.76 0.88 0.83 0.92
Oropharyngeal 178 0.72 0.85 0.79 0.91
Multiple myeloma 176 0.73 0.88 0.83 0.93
Brain 159 0.77 0.92 0.87 0.96
Unknown primary 136 0.76 0.87 0.81 0.93
By referral type
‘Two-week’ referral 8241 0.72 0.89 0.88 0.90
‘Emergency’ 1642 0.72 o0.0001b 0.88 0.87 0.90
‘Routine’ 2030 0.67 0.85 0.83 0.87
‘Other’ 1122 0.67 0.88 0.85 0.90
Abbreviations: AUC¼ area under curve; CI¼ confidence interval; ROC¼ receiver–operator characteristic.
aFor this analysis, the number of pre-referral consultations was dichotomised into 3þ vs 1–2 pre-referral consultation categories. Sensitivity analysis indicated that ROC AUC values were similar
when other binary outcomes (e.g., ‘2þ ’ vs 1, or ‘4þ ’ vs 1, 2 or 3) were used, see Online Supplementary Information.
bFor any cancer type, and for any referral type.
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The findings support efforts to improve the timeliness of
diagnosis by improving the sensitivity of the appraisal of cancer
symptoms by general practitioners, for example, using clinical
decision support tools (Hamilton, 2009; Hippisley-Cox and
Coupland, 2012). Raising awareness of the importance of persistent
symptoms among patients may also help reduce between-
consultation intervals (and therefore improve timeliness of
diagnosis), although such improvements may not necessarily
reduce the number of pre-referral consultations. Research and
policy initiatives can be further prioritised, focusing on patients
with cancers that are more ‘difficult-to-suspect’ because of poor
symptom specificity (e.g., multiple myeloma, lung, stomach and
pancreatic cancer), which are typically associated with longer
primary care intervals and greater number of pre-referral
consultations (Lyratzopoulos et al, 2012).
In conclusion, both the number of pre-referral consultations
and primary care interval are important measures of the timeliness
of cancer diagnosis and are inter-related. Improving the sensitivity
of symptom appraisal by general practitioners to detect cancer
symptoms should be prioritised by research and policy initiatives.
Development and evaluation of interventions can particularly focus
on patients with difficult-to-suspect cancers.
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